CD8-Targeted mRNA Nanoparticles Reprogram T Cells In Vivo to Fight Blood Cancers
Scientists engineered lipid nanoparticles to deliver CAR-encoding mRNA directly to CD8+ T cells in the bloodstream, bypassing costly ex vivo manufacturing.
Summary
Researchers at Sanofi developed CD8-targeted lipid nanoparticles (LNPs) carrying mRNA that encodes a novel CD22 chimeric antigen receptor (CAR). Using a nanobody-based targeting moiety, the LNPs selectively transfect CD8+ T cells in vivo, inducing transient but functional CAR expression without ex vivo cell manipulation. In a humanized mouse model bearing Nalm6 leukemia tumors, non-stimulated T cells reprogrammed entirely in vivo suppressed tumor growth. The platform supports repeated dosing, limits off-target mRNA expression, and is designed to be adaptable to multiple cancer antigens and disease indications — potentially transforming CAR-T therapy from a complex, personalized manufacturing process into an off-the-shelf injectable treatment.
Detailed Summary
Conventional CAR-T cell therapies require lengthy and expensive ex vivo manufacturing: a patient's T cells are extracted, genetically engineered, expanded, and re-infused. This process limits access, introduces variability, and does not easily accommodate iterative or repeated dosing. The current study from Sanofi proposes a fundamentally different approach: deliver CAR-encoding mRNA directly to circulating T cells inside the patient's body using targeted lipid nanoparticles.
The platform employs a NANOBODY VHH (variable heavy domain of heavy chain antibody fragment) as a targeting moiety displayed on the surface of mRNA-loaded LNPs. This nanobody is specific to CD8, ensuring that CAR mRNA is preferentially delivered to cytotoxic CD8+ T cells rather than to off-target immune or non-immune cells. The mRNA encodes a novel CD22-targeting CAR, making it relevant to B cell hematologic malignancies such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma, where CD22 is broadly expressed on malignant cells.
In vitro experiments demonstrated that the CD8-targeted LNPs achieved selective and efficient transfection of CD8+ T cells, resulting in surface CAR expression and functional cytotoxic activity against CD22-expressing target cells. The transient nature of mRNA-based expression — as opposed to stable viral integration — provides an important safety advantage, as CAR expression naturally declines over days, reducing risks of prolonged on-target off-tumor toxicity.
In a humanized Nalm6 leukemia mouse model, intravenous administration of CD8-targeted mRNA-LNPs reprogrammed endogenous T cells in vivo without prior ex vivo stimulation or expansion. These in vivo reprogrammed T cells demonstrated meaningful tumor growth inhibition, validating the therapeutic potential of the approach in a living system. Importantly, the formulation was compatible with repeated dosing, a critical feature for managing tumor antigen escape and maintaining durable responses.
The authors position this platform as broadly adaptable: the modular design allows substitution of the CAR mRNA payload or the targeting nanobody to address different tumor antigens or cell types. Key limitations include the transient expression window of mRNA (necessitating repeated dosing for sustained effect), the use of a humanized mouse model that may not fully recapitulate human immunology, and the need to demonstrate efficacy and safety in non-human primates and ultimately clinical trials. Nevertheless, this work represents a significant conceptual and technical advance toward making CAR-T therapy accessible as a scalable, off-the-shelf injectable medicine.
Key Findings
- CD8-targeted nanobody-LNPs selectively deliver CAR mRNA to CD8+ T cells in vitro and in vivo with minimal off-target expression.
- In vivo reprogrammed T cells expressing a novel CD22 CAR suppressed Nalm6 leukemia tumor growth in a humanized mouse model.
- mRNA-based CAR expression is transient, reducing prolonged toxicity risk while supporting repeated dosing strategies.
- No ex vivo T cell stimulation or expansion was required, bypassing the costly personalized manufacturing process of current CAR-T therapies.
- The modular platform is potentially adaptable to other antigens and diseases beyond hematologic malignancies.
Methodology
The study used nanobody VHH-functionalized mRNA-LNPs targeting CD8 to transfect T cells in vitro and in a humanized Nalm6 leukemia mouse model in vivo. CAR expression, selectivity, and tumor inhibition were assessed using flow cytometry, cytotoxicity assays, and tumor growth monitoring. Repeated dosing feasibility and off-target cell transfection were also evaluated.
Study Limitations
Efficacy was demonstrated only in a humanized mouse model, which may not fully reflect human immune responses or tumor microenvironments. The transient nature of mRNA expression requires repeated dosing to maintain anti-tumor activity, raising questions about long-term immune tolerization. Clinical translation will require safety and pharmacokinetic validation in non-human primates and human trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.